<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03974854</url>
  </required_header>
  <id_info>
    <org_study_id>P/2018/395</org_study_id>
    <nct_id>NCT03974854</nct_id>
  </id_info>
  <brief_title>Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma</brief_title>
  <acronym>ALIX</acronym>
  <official_title>Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma (ALIX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current standard of care for patients with metastatic Pancreatic Ductal AdenoCarcinoma (PDAC)&#xD;
      is chemotherapy, preferential regimen being FOLFIRINOX (5-fluorouracil, leucovorin,&#xD;
      irinotecan, and oxaliplatin). Due to more hematologic (neutropenia) and gastrointestinal&#xD;
      toxicities, FOLFIRINOX is only administered in fit patients (age &lt; 75 years, ECOG Performance&#xD;
      status 0-1, and bilirubin &lt; 1.5 ULN).&#xD;
&#xD;
      However, elderly or frail patients represent more than half of patients with PDAC and are&#xD;
      treated with gemcitabine monochemotherapy. Maintaining more than one drug (polychemotherapy)&#xD;
      may improve survival and quality of life in this population.&#xD;
&#xD;
      ALIX is a non-comparative randomized 2:1 phase II study. This study will assess the efficacy&#xD;
      and safety of the polychemotherapy with XELOXIRI-3 versus gemcitabine as first-line&#xD;
      chemotherapy in elderly or frail patients with locally advanced or metastatic PDAC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 months Progression-Free Survival (PFS) rate</measure>
    <time_frame>6 months after the date of initiation of treatment (1st day of 1st cycle of chemotherapy)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A: XELOXIRI-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capecitabine 625 mg/m2 twice daily on days 1-7 oxaliplatine 85 mg/m2 on Day 1 irinotecan 90 mg/m2 on Day 3, every 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mg / m2 on D1, D8 and D15, every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOXIRI-3</intervention_name>
    <description>chemotherapy with XELOXIRI-3 regimen</description>
    <arm_group_label>Arm A: XELOXIRI-3</arm_group_label>
    <other_name>Capecitabine</other_name>
    <other_name>Oxaliplatine</other_name>
    <other_name>Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>chemotherapy with Gemcitabine regimen</description>
    <arm_group_label>Arm B: Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria :&#xD;
&#xD;
          -  Histologically proven pancreatic ductal adenocarcinoma&#xD;
&#xD;
          -  Locally Advanced or metastatic disease&#xD;
&#xD;
          -  Measurable disease according to RECIST v1.1 criteria&#xD;
&#xD;
          -  Age ≥ 75 years;&#xD;
&#xD;
        OR age between 65 and 75 years AND with at least one frailty contraindication to the&#xD;
        administration of chemotherapy with FOLFIRINOX:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance status (ECOG-PS) 2&#xD;
&#xD;
          -  Total serum bilirubin &gt; 1.5 ULN (biliary drainage allowed)&#xD;
&#xD;
          -  Clinico-biological frailty criteria:&#xD;
&#xD;
          -  weight loss &gt; 10% in 6 months or &gt; 5% in 1 month&#xD;
&#xD;
          -  or body mass index (BMI) ≤ 21&#xD;
&#xD;
          -  or serum albumin &lt; 30 g/L&#xD;
&#xD;
          -  or ADL (Activities of Daily Living) score &lt; 6&#xD;
&#xD;
               -  Eligible for gemcitabine as first-line chemotherapy&#xD;
&#xD;
               -  Registration in a national health care system&#xD;
&#xD;
               -  Written informed consent obtained from the patient prior to performing any&#xD;
                  protocol-related procedures&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 65 years&#xD;
&#xD;
          -  Localized non-metastatic cancer&#xD;
&#xD;
          -  ECOG-PS 3-4&#xD;
&#xD;
          -  Previous treatment For advanced stage (locally advanced or metastatic): chemotherapy,&#xD;
             radiochemotherapy; For localized stage: FOLFIRINOX chemotherapy (neoadjuvant or&#xD;
             adjuvant); adjuvant chemotherapy with gemcitabine before relapse is permitted (provide&#xD;
             it has been administered more than 6 months before)&#xD;
&#xD;
          -  Uncontrolled intercurrent cardiovascular disease&#xD;
&#xD;
          -  Known or suspected allergy or hypersensitivity to any of the study drugs&#xD;
             (capecitabine, oxaliplatin, irinotecan, gemcitabine)&#xD;
&#xD;
          -  Bowel obstruction or sub-obstruction or impossible oral treatment&#xD;
&#xD;
          -  Prior peripheral neuropathy of grade ≥ 2&#xD;
&#xD;
          -  Known complete dihydropyrimidine dehydrogenase (DPD) or UDP-glycosyltransferase 1&#xD;
             polypeptide A1 (UGT1A1) deficiency&#xD;
&#xD;
          -  Inadequate hematological, hepatic, and renal functions&#xD;
&#xD;
          -  Psychiatric illness/social situations that would limit compliance with study&#xD;
             requirement, substantially increase risk of incurring AEs (Adverse Events) or&#xD;
             compromise the ability of the patient to give written informed consent&#xD;
&#xD;
          -  Tutelage or guardianship&#xD;
&#xD;
          -  Diagnosis of any second malignancy within the last 2 years, except for adequately&#xD;
             treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix&#xD;
             uteri&#xD;
&#xD;
          -  Current participation in another clinical trial using therapeutic experimental agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angélique VIENOT, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angélique Dr VIENOT</last_name>
    <phone>+33381479999</phone>
    <email>a3vienot@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion JACQUIN</last_name>
    <email>m1jacquin@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Besançon</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelique VIENOT</last_name>
    </contact>
    <investigator>
      <last_name>Angélique VIENOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche-Comté</name>
      <address>
        <city>Montbéliard</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelique VIENOT, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Christophe BORG, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie HUSSON WETZEL</last_name>
    </contact>
    <investigator>
      <last_name>Stephanie HUSSON-WETZEL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Lopez, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Anthony LOPEZ, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BOUCHE, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Olivier BOUCHE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

